NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
AUREA – No Added Benefit of Short-Term OAC Post-TAVI in Patients Without OAC Indication
Davide Capodanno/X
Jul 8, 2025, 07:56

AUREA – No Added Benefit of Short-Term OAC Post-TAVI in Patients Without OAC Indication

Davide Capodanno, Professor of Cardiology at University of Catania, Italy has posted on X:

“In the randomized, open-label AUREA trial, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism in patients without an indication for OAC. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol.”

AUREA - No Added Benefit of Short-Term OAC Post-TAVI in Patients Without OAC Indication

You can read the Full Article here.

Explore more on Hemostasis Today.

antiplatelet strategy AUREA trial Davide Capodanno Direct oral anticoagulants (DOACs) Hematology Hemostasis Hemostasis Today thrombosis
NewsFeed